Using advanced imaging to evaluate Kaposi sarcoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the feasibility of using a SkinScan3D camera to capture detailed 3D images of Kaposi sarcoma lesions. The study focuses on patients diagnosed with Kaposi sarcoma who have multiple skin lesions, as traditional 2D imaging may not adequately represent the complexity of these tumors. By obtaining accurate 3D imaging, the study seeks to improve the evaluation of treatment responses and disease progression in patients with this condition.

Why it matters

Who can join: the full rules

Eligibility Criteria:

* Have been diagnosed with histologically or cytologically proven Kaposi sarcoma (KS).
* Patients may be off treatment or on treatment for their KS.
* Has at least 3 cutaneous Kaposi sarcoma lesions.
* At least 18 years of age.
* Ability to understand and willingness to sign an IRB approved written informed consent document.

Where it's running

• Washington University School of Medicine
  St Louis, Missouri, United States Recruiting

Study contacts

• Principal investigator: Lee Ratner, M.D., Ph.D. — Washington University School of Medicine
• Study coordinator: Lee Ratner, M.D., Ph.D.
• Email: lratner@wustl.edu
• Phone: 314-362-8836

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• CYT107 (recombinant interleukin-7) to treat Kaposi sarcoma in adults with HIV and poor T‑cell recovery

  This trial tests whether CYT107, a laboratory-made interleukin-7, can shrink Kaposi sarcoma tumors in adults with HIV who have poor T‑cell recovery.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07308886

• Using AI to improve monitoring of Kaposi Sarcoma

  This study is testing a new low-cost device that uses AI to help doctors better track and measure Kaposi Sarcoma in patients with darker skin in Uganda and Kenya.

  Recruiting Washington University School of Medicine · Kisumu and 1 other locations · NCT06898203

• Propranolol for treating Kaposi sarcoma in adults

  This trial will test whether the oral beta‑blocker propranolol can shrink Kaposi sarcoma lesions in adults, including people living with HIV.

  Recruiting Phase 2 Washington University School of Medicine · St Louis, Missouri · NCT06445166

• Understanding the natural history of Kaposi Sarcoma

  This study looks at how Kaposi Sarcoma affects people with weakened immune systems, like those with HIV, by tracking their symptoms and health over time.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06375122

• Peer support program to improve cancer diagnosis and treatment for young people with HIV in Zambia

  This study is testing a peer support program to help young people with HIV in Zambia get diagnosed and treated for cancer more effectively.

  Recruiting Implenomics · Lusaka · NCT06004011

• MQ710 with or without pembrolizumab for advanced skin and other solid tumors

  This will test different doses of MQ710, alone or together with pembrolizumab, in adults with advanced or recurrent solid tumors (including skin cancers) to find a safe dose with mild side effects.

  Recruiting at 5 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT05859074

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.